Stryker Corp
SYK
View Detailed Chart
354.300USD
-3.530-0.99%
Close 01/29, 16:00（ET）Quotes delayed by 15 min
135.48BMarket Cap
45.99P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.99%
5 Days
-1.22%
1 Month
+0.51%
6 Months
-11.55%
Year to Date
+0.81%
1 Year
-9.40%
View Detailed Chart
TradingKey Stock Score of Stryker Corp
Currency: USD Updated: 2026-01-28Key Insights
Stryker Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 24 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 427.79.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Stryker Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Stryker Corp Highlights
StrengthsRisks
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.47% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 22.59B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 41.30%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 41.30%.
Overvalued
The company’s latest PE is 46.44, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 313.23M shares, decreasing 1.44% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 9.43K shares of this stock.
Analyst Rating
Based on
32
analysts
Buy
Current Rating
427.792
Target Price
+20.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Stryker Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Stryker Corp Info
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
Ticker SymbolSYK
CompanyStryker Corp
CEOLobo (Kevin A)
Websitehttps://www.stryker.com/
Related Instruments
-0.59%
-2.61%
+0.04%
-2.78%
-2.19%
-1.56%
+0.21%
-1.77%
+0.55%
+1.50%
-0.41%
+0.45%
-1.33%
-0.41%
-1.60%
-0.45%
+0.91%
-0.45%
-0.04%Popular Symbols
258.280
+1.840 (+0.72%)
192.510
+0.990 (+0.52%)
83780.120
-398.830 (-0.47%)
278.410
-1.290 (-0.46%)
2801.040
-2.310 (-0.08%)
416.560
-14.900 (-3.45%)
5358.390
-35.210 (-0.65%)
64.832
-0.406 (-0.62%)
1.193
-0.003 (-0.27%)
153.574
+0.462 (+0.30%)
